| Cobalamin deficiency: clinical picture and radiological findings C Briani, C Dalla Torre, V Citton, R Manara, S Pompanin, G Binotto, ... Nutrients 5 (11), 4521-4539, 2013 | 414 | 2013 |
| Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection C Agostini, F Calabrese, F Rea, M Facco, A Tosoni, M Loy, G Binotto, ... The American journal of pathology 158 (5), 1703-1711, 2001 | 257 | 2001 |
| Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas L Trentin, A Cabrelle, M Facco, D Carollo, M Miorin, A Tosoni, P Pizzo, ... Blood 104 (2), 502-508, 2004 | 198 | 2004 |
| Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain S Soverini, C De Benedittis, K Machova Polakova, A Brouckova, D Horner, ... Blood, The Journal of the American Society of Hematology 122 (9), 1634-1648, 2013 | 186 | 2013 |
| Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis F Palandri, M Breccia, M Bonifacio, N Polverelli, EM Elli, G Benevolo, ... Cancer 126 (6), 1243-1252, 2020 | 134 | 2020 |
| Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes GP Fadini, M Albiero, L Menegazzo, E Boscaro, S Vigili de Kreutzenberg, ... Circulation research 108 (9), 1112-1121, 2011 | 126 | 2011 |
| Differences among young adults, adults and elderly chronic myeloid leukemia patients F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ... Annals of Oncology 26 (1), 185-192, 2015 | 105 | 2015 |
| Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study S Soverini, L Bavaro, C De Benedittis, M Martelli, A Iurlo, N Orofino, ... Blood, The Journal of the American Society of Hematology 135 (8), 534-541, 2020 | 92 | 2020 |
| Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP M Baccarani, E Abruzzese, V Accurso, F Albano, M Annunziata, S Barulli, ... Blood advances 3 (24), 4280-4290, 2019 | 83 | 2019 |
| Quality of life and physicians' perception in myelodysplastic syndromes EN Oliva, C Finelli, V Santini, A Poloni, V Liso, D Cilloni, S Impera, ... American journal of blood research 2 (2), 136, 2012 | 74 | 2012 |
| Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE … G Caocci, O Mulas, E Abruzzese, L Luciano, A Iurlo, I Attolico, ... Hematological oncology 37 (3), 296-302, 2019 | 66 | 2019 |
| Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia L Quotti Tubi, S Canovas Nunes, A Brancalion, E Doriguzzi Breatta, ... Leukemia 31 (2), 292-300, 2017 | 64 | 2017 |
| Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients M Breccia, F Efficace, S Sica, E Abruzzese, M Cedrone, D Turri, M Gobbi, ... Leukemia research 39 (10), 1055-1059, 2015 | 61 | 2015 |
| Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity L Trentin, M Miorin, M Facco, I Baesso, S Carraro, A Cabrelle, N Maschio, ... British journal of haematology 138 (5), 594-602, 2007 | 59 | 2007 |
| Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis F Palandri, GA Palumbo, EM Elli, N Polverelli, G Benevolo, B Martino, ... Blood cancer journal 11 (1), 4, 2021 | 55 | 2021 |
| Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib R Latagliata, M Breccia, F Castagnetti, F Stagno, L Luciano, A Gozzini, ... Leukemia research 35 (9), 1164-1169, 2011 | 55 | 2011 |
| Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients N Polverelli, GA Palumbo, G Binotto, E Abruzzese, G Benevolo, ... Hematological Oncology 36 (3), 561-569, 2018 | 52 | 2018 |
| Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study R Latagliata, D Ferrero, A Iurlo, F Cavazzini, F Castagnetti, E Abruzzese, ... Drugs & aging 30, 629-637, 2013 | 47 | 2013 |
| Ifosfamide and cyclophosphamide: effects on immunosurveillance G Binotto, L Trentin, G Semenzato Oncology 65 (Suppl. 2), 17-20, 2003 | 46 | 2003 |
| Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free … M Breccia, L Luciano, R Latagliata, F Castagnetti, D Ferrero, F Cavazzini, ... Leukemia Research 38 (10), 1173-1176, 2014 | 45 | 2014 |
